HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Aug. 4, 2005-- Infrared Sciences Inc. completes Series B Preferred Stock financing round for its proprietary infrared imaging system Infrared Sciences Corporation (“ISC”) has announced that it has completed a $2.1 million Series B Preferred Stock financing, acquiring the capital necessary to continue introducing Sentinel BreastScan(TM) to a broader market of doctors and patients. ISC completed a $1 million Series A Stock financing in October, 2004. Utilizing infrared imaging and proprietary software employing artificial intelligence techniques, Sentinel BreastScan(TM) is designed to be used as an adjunctive test with mammography, ultrasound or clinical examination for the early detection of breast cancer. It is an FDA-approved, non-invasive touchless procedure offered to women of any age, to help determine current breast health. The patient simply sits in a chair, facing the Sentinel BreastScan unit for a few minutes. Test results are immediately available in the form of a fully-interpreted, objective report, to assist in the doctor’s determination of breast health.
